The Drug Enforcement Administration’s (DEA) Liaison and Policy Section has asked that the National Association of Chain Drug Stores (NACDS) to share information regarding its Pharmacy Diversion Awareness Conferences that will be held in August with member companies. Read More »
Pfizer Inc. recently announced that its third Phase III study of XELJANZ (tofacitinib citrate), Oral Clinical Trials for tofacitinib in ulcerative colitis (OCTAVE) Sustain, has turned in positive result Read More »
Galmed Pharmaceuticals has announced that Professor Ran Oren, M.D., has been named its Chief Medical Officer (CMO). Read More »
Ardelyx Inc. recently announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its composition of matter patent application for RDX227675. Read More »
With only the slightest of increases, Medicare recently announced that the average monthly cost for a Medicare Part D prescription drug plan in 2017 is projected to remain reasonably stable at approximately $34. Read More »
Argentum Pharmaceuticals recently announced that it, along with its manufacturing partner KVK Tech, has been granted a petition for inter partes review (IPR) against all challenged claims of the sole patent that covers Alcon’s PAZEO by the U.S. Patent & Trademark Office (PTO). Read More »
Basal cell carcinoma nevus syndrome patients show positive results after 16 weeks in the study. Read More »
Collaboration to contribute to Evelo's cancer-associated bacteria library. Read More »
Vaccines available daily; insurance may cover the vaccination. Read More »
Bamboo research is focused on gene therapy for neuromuscular and central nervous system conditions. Read More »
Triumph Pharmaceuticals this week announced that Ray Barrett, Biomedical Systems chairman, has accepted its position of chairman. Read More »
Aetna and Humana this week announced that the two companies have agreed to sell Medicare Advantage assets to Molina Healthcare, Inc. for approximately $117 million, which is based on the estimated number of members in the plans covered in the transactions. Read More »
Amgen and Advaxis has announced the finalization of a worldwide agreement for the development and commercialization of Advaxis’ ADXS-NEO, a novel, preclinical investigational immunotherapy developed for the treatment of cancer. Read More »
To expedite and encourage the growth of independent local pharmacies in an evolving health care atmosphere, the Alexandria, Virginia-based National Community Pharmacists Association (NCPA) recently launched a new Innovation Center designed for outreach and education. Read More »
Abbott has introduced its line of next-generation systems, call Alinity. Read More »
DigiTx Partners, a digital health investment firm, recently resulted from a three-way partnership between San Francisco’s DigiTx Partners LLC , Tokyo-based Astellas Pharma Inc. and Boston-based MPM Capital Inc. Read More »
A&D Medical, a worldwide leader in connecting health and biometric measurement devices and services, was on track to reveal its new PlusConnect Wireless Weight Scale at the National Association of Chain Drug Stores (NACDS) conference. Read More »
Proteostasis Therapeutics Inc. recently announced the successful completion of an important preclinical goal in its partnerships with Astellas Pharma Inc. Read More »
.jpg)
The U.S. Food and Drug Administration (FDA) recently approved Merck’s anti-PD-1 therapy, KEYTRUDA, for use in fixed doses of 200 mg on a tri-weekly basis for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients. Read More »
Proteostasis Therapeutics Inc. recently announced key leadership appointments. Read More »
Alerts Sign-up
